Market overview
The global CRISPR-integrated gene editing delivery devices market is worth USD 366 mn in 2026 and is forecast to reach USD 994 mn by 2036, growing at a 10.5% CAGR. United States is the largest country market and Cartridges, cuvettes and reagents is the largest by product segment.
| Scope | Electroporation instruments and consumables used to deliver CRISPR editors and other payloads into cells: benchtop and large-volume systems, cartridges, cuvettes and reagents for research and cell therapy manufacturing. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 330 mn |
| Value 2026 | USD 366 mn |
| Value 2036 | USD 994 mn |
| CAGR 2026-2036 | 10.5% |
| Volume 2026 | 3,663 thousand runs |
| Volume 2036 | 9,942 thousand runs |
| Average price 2026 | USD 100 per run |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
CRISPR-Integrated Gene Editing Delivery Devices market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 366 mn |
| 2027 | USD 405 mn |
| 2028 | USD 447 mn |
| 2029 | USD 494 mn |
| 2030 | USD 546 mn |
| 2031 | USD 603 mn |
| 2032 | USD 667 mn |
| 2033 | USD 737 mn |
| 2034 | USD 814 mn |
| 2035 | USD 900 mn |
| 2036 | USD 994 mn |
CRISPR-Integrated Gene Editing Delivery Devices market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Benchtop electroporators | 30.0% | 22.1% | USD 110 mn | 7.2% |
| Large-volume flow electroporation | 24.0% | 33.2% | USD 88 mn | 14.1% |
| Cartridges, cuvettes and reagents | 46.0% | 44.7% | USD 168 mn | 10.2% |
By end use
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cell therapy manufacturing | 38.0% | 53.1% | USD 139 mn | 14.3% |
| Academic and basic research | 40.0% | 27.2% | USD 147 mn | 6.3% |
| Biopharma discovery | 22.0% | 19.7% | USD 81 mn | 9.3% |
By delivery method
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Electroporation systems | 38.0% | 34.0% | USD 139 mn | 9.3% |
| Microfluidic devices | 20.0% | 22.0% | USD 73 mn | 11.6% |
| Lipid nanoparticle formulators | 24.0% | 28.0% | USD 88 mn | 12.2% |
| Viral vector systems | 18.0% | 16.0% | USD 66 mn | 9.2% |
By editing target
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Ex vivo cell editing | 46.0% | 44.0% | USD 168 mn | 10.0% |
| In vivo editing | 34.0% | 36.0% | USD 125 mn | 11.1% |
| Plant and microbial editing | 20.0% | 20.0% | USD 73 mn | 10.5% |
By scale
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Research scale | 46.0% | 38.0% | USD 168 mn | 8.4% |
| Preclinical and process development | 32.0% | 34.0% | USD 117 mn | 11.2% |
| Clinical manufacturing | 22.0% | 28.0% | USD 81 mn | 13.2% |
Top 25 countries for CRISPR-integrated gene editing delivery devices by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 91.0% of 2026 revenue and the 25 countries below together hold 98.3%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 168 mn | 46.0% | USD 454 mn | 10.4% |
| 2 | China | USD 44 mn | 12.0% | USD 142 mn | 12.4% |
| 3 | Germany | USD 26 mn | 7.0% | USD 64 mn | 9.5% |
| 4 | United Kingdom | USD 22 mn | 6.0% | USD 57 mn | 9.9% |
| 5 | Japan | USD 18 mn | 5.0% | USD 43 mn | 8.8% |
| 6 | South Korea | USD 15 mn | 4.0% | USD 44 mn | 11.6% |
| 7 | France | USD 11 mn | 3.0% | USD 27 mn | 9.3% |
| 8 | Switzerland | USD 11 mn | 3.0% | USD 28 mn | 9.7% |
| 9 | Canada | USD 11 mn | 3.0% | USD 28 mn | 9.7% |
| 10 | Netherlands | USD 7.3 mn | 2.0% | USD 19 mn | 9.9% |
| 11 | Australia | USD 5.0 mn | 1.4% | USD 13 mn | 10.2% |
| 12 | Belgium | USD 4.1 mn | 1.1% | USD 11 mn | 10.1% |
| 13 | Sweden | USD 3.3 mn | 0.9% | USD 8.8 mn | 10.1% |
| 14 | Singapore | USD 2.8 mn | 0.8% | USD 8.1 mn | 11.3% |
| 15 | Taiwan | USD 2.2 mn | 0.6% | USD 6.7 mn | 11.5% |
| 16 | Denmark | USD 1.8 mn | 0.5% | USD 4.9 mn | 10.3% |
| 17 | Israel | USD 1.8 mn | 0.5% | USD 4.7 mn | 10.0% |
| 18 | Spain | USD 1.4 mn | 0.4% | USD 3.6 mn | 10.2% |
| 19 | Italy | USD 1.0 mn | 0.3% | USD 2.7 mn | 10.1% |
| 20 | Brazil | USD 0.84 mn | 0.2% | USD 2.5 mn | 11.4% |
| 21 | Austria | USD 0.70 mn | 0.2% | USD 1.8 mn | 9.9% |
| 22 | Ireland | USD 0.55 mn | 0.1% | USD 1.5 mn | 10.5% |
| 23 | Russia | USD 0.55 mn | 0.1% | USD 1.6 mn | 11.2% |
| 24 | Poland | USD 0.48 mn | 0.1% | USD 1.4 mn | 11.3% |
| 25 | Mexico | USD 0.33 mn | 0.09% | USD 0.99 mn | 11.7% |
| Rest of world | USD 6.2 mn | 1.7% | USD 17 mn | 10.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Thermo Fisher Scientific
- Lonza
- Bio-Rad Laboratories
Group 2: Regional and specialist players
- MaxCyte
- Harvard Bioscience
- Nepa Gene
- Mirus Bio
- Eppendorf
Group 3: Emerging and niche players
- Celetrix
- Avectas
- Kytopen
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the CRISPR-integrated gene editing delivery devices market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.5% is calculated from the resulting values.
The market is divided by product, by end use, by delivery method, by editing target, by scale. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the CRISPR-integrated gene editing delivery devices market?
The global CRISPR-integrated gene editing delivery devices market is estimated at USD 330 mn in 2025 and USD 366 mn in 2026.
How fast will the CRISPR-integrated gene editing delivery devices market grow?
It is forecast to reach USD 994 mn by 2036, a compound annual growth rate of 10.5% from 2026, an increase of USD 628 mn.
Which country is the largest market for CRISPR-integrated gene editing delivery devices?
United States is the largest market by revenue at USD 168 mn in 2026, 46.0% of the global total. The three largest countries together hold 65.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 12.4% a year from 2026 to 2036.
Which CRISPR-integrated gene editing delivery devices segment is largest?
In the by product split, Cartridges, cuvettes and reagents is the largest segment with 46.0% of 2026 revenue.
Who are the leading CRISPR-integrated gene editing delivery devices companies?
Global leaders include Thermo Fisher Scientific, Lonza, Bio-Rad Laboratories.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Smart Breast ImagingUSD 366 mn · 19.0% CAGR
- Adaptive StrollerUSD 362 mn · 6.0% CAGR
- Veterinary Dental EquipmentUSD 371 mn · 5.8% CAGR
- Mixed Reality Navigation PlatformsUSD 378 mn · 17.0% CAGR
- Dental AutoclavesUSD 355 mn · 4.5% CAGR
- AI-Assisted Clinical Trial Protocol DesignUSD 378 mn · 20.0% CAGR
- UV-C Disinfection RobotsUSD 382 mn · 7.0% CAGR
- MRI-based Quantitative BiomarkersUSD 348 mn · 15.0% CAGR